NewsSOS
Medtronic plc reported first-quarter fiscal 2027 organic revenue growth of 13.7%, a figure that includes an estimated 670-basis-point benefit from an extra selling week.
Management stated that excluding this calendar benefit, the quarter delivered the company's best performance in nearly eight years, excluding pandemic-related periods.
The medical device manufacturer, which has a market capitalization of $120.53 billion, achieved this result while maintaining a Zacks Rank 3 Hold rating.
Cardiac ablation emerged as the primary growth driver during the period.
Keep reading